Literature DB >> 25180992

The fate of ritonavir in the presence of darunavir.

D N Nguyen1, G Van den Mooter2.   

Abstract

This study was the first investigation into the potential of a fixed dose combination of ritonavir and darunavir in the form of dispersible powders prepared by spray drying. A common polymer (hydroxypropyl methylcellulose, polyvinylpyrrolidone, and polyvinylpyrrolidone-vinyl acetate 64) was formulated with either ritonavir or darunavir or a combination of ritonavir and darunavir. The influence of these polymers on the supersaturation level of ritonavir and darunavir was investigated. The concentration levels of ritonavir and darunavir during these tests dropped instantly to a plateau which could be considered as amorphous solubility. Besides, the presence of darunavir always decreased the supersaturation level of ritonavir and vice versa no matter which polymers were used. Moreover, the rate and extent of release of both ritonavir and darunavir from ternary spray-dried powders were less than the releases from binary spray-dried powders. Intermolecular interaction between ritonavir and darunavir was ruled out by (1)H NMR study which means that the decrease in supersaturation level or release must be at least partially attributed to the mediated solvent process. In order to restrict the mutual influence between darunavir and ritonavir, a complex of both ritonavir and darunavir with (2-hydroxypropyl)-β-cyclodextrin was prepared and improved the dissolution rate of both ritonavir and darunavir.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cyclodextrins; Darunavir; Ritonavir; Solid dispersion; Solubility; Spray drying

Mesh:

Substances:

Year:  2014        PMID: 25180992     DOI: 10.1016/j.ijpharm.2014.08.062

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  6 in total

1.  New Perspectives for Fixed Dose Combinations of Poorly Water-Soluble Compounds: a Case Study with Ezetimibe and Lovastatin.

Authors:  Manoela K Riekes; Axel Engelen; Bernard Appeltans; Patrick Rombaut; Hellen K Stulzer; Guy Van den Mooter
Journal:  Pharm Res       Date:  2016-02-08       Impact factor: 4.200

2.  Leaching of Lopinavir Amorphous Solid Dispersions in Acidic Media.

Authors:  Na Li; James D Ormes; Lynne S Taylor
Journal:  Pharm Res       Date:  2016-03-29       Impact factor: 4.200

3.  Controlled Solvent Removal from Antiviral Drugs and Excipients in Solution Enables the Formation of Novel Combination Multi-Drug-Motifs in Pharmaceutical Powders Composed of Lopinavir, Ritonavir and Tenofovir.

Authors:  Jesse Yu; Danni Yu; Sarah Lane; Lisa McConnachie; Rodney J Y Ho
Journal:  J Pharm Sci       Date:  2020-08-10       Impact factor: 3.534

Review 4.  The Need for Pediatric Formulations to Treat Children with HIV.

Authors:  Adrienne F Schlatter; Andrew R Deathe; Rachel C Vreeman
Journal:  AIDS Res Treat       Date:  2016-06-16

5.  Impact of Simulated Intestinal Fluids on Dissolution, Solution Chemistry, and Membrane Transport of Amorphous Multidrug Formulations.

Authors:  Mira El Sayed; Amjad Alhalaweh; Christel A S Bergström
Journal:  Mol Pharm       Date:  2021-10-06       Impact factor: 4.939

Review 6.  Cyclodextrins in the antiviral therapy.

Authors:  László Jicsinszky; Katia Martina; Giancarlo Cravotto
Journal:  J Drug Deliv Sci Technol       Date:  2021-05-20       Impact factor: 3.981

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.